Company: INMB
Filing Date: 2025-10-14
Form Type: DEF 14A
Source: 0001213900-25-098715
Chunk: 12

Company: Inmune Bio, Inc.
Filing Date: 2025-10-14
Form: DEF 14A
Chunk 12
---
 $                | 20.67 |     |             5.69 |

____________ (1)Excludes the number of shares underlying certain outstanding stock options granted under the Plans that will cease to be Eligible Options as of the Repricing Date due to the previously scheduled departures of certain employees.

7 Alternatives considered We considered several alternatives in arriving at this proposal. 1)We could do nothing. We are concerned that if we do not improve the Eligible Option holder’s prospects of receiving long -termvalue from their stock options, we will undermine their long -termcommitment to us. We will also forgo an opportunity to better align their interests with the interests of our stockholders. Also, we considered not repricing the options of former directors, officers and employees. 2)We could limit the Repricing to non -executiveemployees. We believe that excluding executive officers and directors from the Repricing could result in our possibly losing the services of some the most highly -valuedcontributors to our long -termsuccess. 3)Increase cash compensation. To replace underwater equity incentives, we considered whether we could substantially increase cash compensation. However, significant increases in cash compensation would substantially increase our compensation expenses and reduce our cash flow from operations, which could adversely affect our business and operating results. 4)Exchange underwater stock options for new stock options. We also considered implementing a program to exchange underwater stock options for restricted stock units. However, the exchange ratios for such an exchange would likely result in fewer replacement awards being granted and we do not believe such a program would provide sufficient incentives for retention under our current circumstances. In addition, any exchange proposal would require compliance with the SEC’s tender offer rules and result in additional costs, complexities and burdens on our resources. Specifics of the Option Repricing Accordingly, on September 30, 2025, our board of directors, based on the recommendation of our compensation committee, approved, subject to the approval of our stockholders at the Special Meeting, the Option Pricing Proposal. If approved by stockholders, the exercise price per share of Eligible Options (as defined below) would be reduced (the “Repricing”) to an amount equal to one hundred percent (100%) of the closing price of our common stock on the Nasdaq Capital Market on the date of our Special Meeting (the “Repricing Date”), rounded up to the nearest penny (the “Repriced Exercise Price”). There will be no changes to the number of shares underlying the Repriced Options or the vest